Hansa Biopharma Ab Stock Current Liabilities
HNSBF Stock | USD 2.93 0.00 0.00% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Pink Sheet. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma pink sheet.
Hansa |
Hansa Biopharma AB Company Current Liabilities Analysis
Hansa Biopharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Hansa Biopharma Current Liabilities | 19 M |
Most of Hansa Biopharma's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
In accordance with the recently published financial statements, Hansa Biopharma AB has a Current Liabilities of 19 M. This is 98.92% lower than that of the Healthcare sector and 96.5% lower than that of the Biotechnology industry. The current liabilities for all United States stocks is 99.76% higher than that of the company.
Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
All Next | Launch Module |
Hansa Fundamentals
Return On Equity | -0.89 | |||
Return On Asset | -0.27 | |||
Current Valuation | 189.89 M | |||
Shares Outstanding | 52.44 M | |||
Shares Owned By Insiders | 7.37 % | |||
Shares Owned By Institutions | 41.33 % | |||
Price To Earning | (46.57) X | |||
Price To Book | 6.59 X | |||
Price To Sales | 16.29 X | |||
Revenue | 33.88 M | |||
Gross Profit | 116.05 M | |||
EBITDA | (538.83 M) | |||
Net Income | (548.28 M) | |||
Cash And Equivalents | 60.15 M | |||
Cash Per Share | 1.58 X | |||
Debt To Equity | 2.29 % | |||
Current Ratio | 6.42 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (481.17 M) | |||
Earnings Per Share | (0.65) X | |||
Number Of Employees | 150 | |||
Beta | 0.88 | |||
Market Capitalization | 274.8 M | |||
Total Asset | 1.01 B | |||
Working Capital | 86 M | |||
Current Asset | 105 M | |||
Current Liabilities | 19 M | |||
Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |